EGFR alterations in glioblastoma play a role in antitumor immunity regulation
The epidermal growth factor receptor (EGFR) is the most frequently altered gene in glioblastoma (GBM), which plays an important role in tumor development and anti-tumor immune response. While current molecular targeted therapies against the EGFR signaling pathway and its downstream key molecules hav...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1236246/full |
| _version_ | 1797754592944979968 |
|---|---|
| author | Xiao-Peng Li Zheng-Qian Guo Bao-Feng Wang Min Zhao |
| author_facet | Xiao-Peng Li Zheng-Qian Guo Bao-Feng Wang Min Zhao |
| author_sort | Xiao-Peng Li |
| collection | DOAJ |
| description | The epidermal growth factor receptor (EGFR) is the most frequently altered gene in glioblastoma (GBM), which plays an important role in tumor development and anti-tumor immune response. While current molecular targeted therapies against the EGFR signaling pathway and its downstream key molecules have not demonstrated favorable clinical outcomes in GBM. Whereas tumor immunotherapies, especially immune checkpoint inhibitors, have shown durable antitumor responses in many cancers. However, the clinical efficacy is limited in patients carrying EGFR alterations, indicating that EGFR signaling may involve tumor immune response. Recent studies reveal that EGFR alterations not only promote GBM cell proliferation but also influence immune components in the tumor microenvironment (TME), leading to the recruitment of immunosuppressive cells (e.g., M2-like TAMs, MDSCs, and Tregs), and inhibition of T and NK cell activation. Moreover, EGFR alterations upregulate the expression of immunosuppressive molecules or cytokines (such as PD-L1, CD73, TGF-β). This review explores the role of EGFR alterations in establishing an immunosuppressive TME and hopes to provide a theoretical basis for combining targeted EGFR inhibitors with immunotherapy for GBM. |
| first_indexed | 2024-03-12T17:35:37Z |
| format | Article |
| id | doaj.art-7c9b4740822b4b458238da893be38773 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T17:35:37Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7c9b4740822b4b458238da893be387732023-08-04T11:44:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.12362461236246EGFR alterations in glioblastoma play a role in antitumor immunity regulationXiao-Peng LiZheng-Qian GuoBao-Feng WangMin ZhaoThe epidermal growth factor receptor (EGFR) is the most frequently altered gene in glioblastoma (GBM), which plays an important role in tumor development and anti-tumor immune response. While current molecular targeted therapies against the EGFR signaling pathway and its downstream key molecules have not demonstrated favorable clinical outcomes in GBM. Whereas tumor immunotherapies, especially immune checkpoint inhibitors, have shown durable antitumor responses in many cancers. However, the clinical efficacy is limited in patients carrying EGFR alterations, indicating that EGFR signaling may involve tumor immune response. Recent studies reveal that EGFR alterations not only promote GBM cell proliferation but also influence immune components in the tumor microenvironment (TME), leading to the recruitment of immunosuppressive cells (e.g., M2-like TAMs, MDSCs, and Tregs), and inhibition of T and NK cell activation. Moreover, EGFR alterations upregulate the expression of immunosuppressive molecules or cytokines (such as PD-L1, CD73, TGF-β). This review explores the role of EGFR alterations in establishing an immunosuppressive TME and hopes to provide a theoretical basis for combining targeted EGFR inhibitors with immunotherapy for GBM.https://www.frontiersin.org/articles/10.3389/fonc.2023.1236246/fullglioblastomaepidermal growth factor receptorimmunosuppressiontumor microenvironmentimmune cell |
| spellingShingle | Xiao-Peng Li Zheng-Qian Guo Bao-Feng Wang Min Zhao EGFR alterations in glioblastoma play a role in antitumor immunity regulation Frontiers in Oncology glioblastoma epidermal growth factor receptor immunosuppression tumor microenvironment immune cell |
| title | EGFR alterations in glioblastoma play a role in antitumor immunity regulation |
| title_full | EGFR alterations in glioblastoma play a role in antitumor immunity regulation |
| title_fullStr | EGFR alterations in glioblastoma play a role in antitumor immunity regulation |
| title_full_unstemmed | EGFR alterations in glioblastoma play a role in antitumor immunity regulation |
| title_short | EGFR alterations in glioblastoma play a role in antitumor immunity regulation |
| title_sort | egfr alterations in glioblastoma play a role in antitumor immunity regulation |
| topic | glioblastoma epidermal growth factor receptor immunosuppression tumor microenvironment immune cell |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1236246/full |
| work_keys_str_mv | AT xiaopengli egfralterationsinglioblastomaplayaroleinantitumorimmunityregulation AT zhengqianguo egfralterationsinglioblastomaplayaroleinantitumorimmunityregulation AT baofengwang egfralterationsinglioblastomaplayaroleinantitumorimmunityregulation AT minzhao egfralterationsinglioblastomaplayaroleinantitumorimmunityregulation |